Behind the App Note: Biosimilar Comparison of Commercially-sourced Reference Standards 

This video covers the details behind a study entitled "Biosimilar Comparison of Commercially-sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA Product".
Dr. Patrick King of RedShiftBio discusses how the study confidently detected less than 2% structural difference between samples to correctly predict activity amongst the commercially sourced materials. Furthermore, MMS successfully identified 5 of 13 BSA biosimilar samples that retained acceptable activity upon inclusion in the ELISA product through structural comparison to a reference of known activity.